Literature DB >> 27136189

Changes in patient backgrounds may increase the incidence of HCC after SVR in the era of IFN-free therapy for HCV.

Hidenori Toyoda1, Takashi Kumada1, Toshifumi Tada1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27136189     DOI： 10.1002/hep.28632

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  14 in total

1.  Is direct acting antiviral therapy for hepatitis c viral infection associated with increased risk of hepatocellular carcinoma before or after liver transplantation?

Authors:  Ashokkumar Jain; Danielle Miller; Zakiyah Kadry
Journal:  Hepatobiliary Surg Nutr       Date:  2019-10       Impact factor: 7.293

2.  Drug Treatment for Chronic Hepatitis C Infection and Cancer Risk.

Authors:  Marcus-Alexander Wörns; Peter Robert Galle; Stefan Zeuzem; Peter Schirmacher; Michael Manns; Arndt Vogel
Journal:  Dtsch Arztebl Int       Date:  2017-09-04       Impact factor: 5.594

3.  Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma.

Authors:  Kenji Ikeda; Yusuke Kawamura; Masahiro Kobayashi; Yoko Kominami; Shunichiro Fujiyama; Hitomi Sezaki; Tetsuya Hosaka; Norio Akuta; Satoshi Saitoh; Fumitaka Suzuki; Yoshiyuki Suzuki; Yasuji Arase; Hiromitsu Kumada
Journal:  Dig Dis Sci       Date:  2017-09-07       Impact factor: 3.199

Review 4.  Genetic basis of hepatitis virus-associated hepatocellular carcinoma: linkage between infection, inflammation, and tumorigenesis.

Authors:  Haruhiko Takeda; Atsushi Takai; Tadashi Inuzuka; Hiroyuki Marusawa
Journal:  J Gastroenterol       Date:  2016-10-06       Impact factor: 7.527

5.  Risk of de novo Hepatocellular Carcinoma after HCV Treatment with Direct-Acting Antivirals.

Authors:  Fabian Finkelmeier; Georg Dultz; Kai-Henrik Peiffer; Bernd Kronenberger; Franziska Krauss; Stefan Zeuzem; Christoph Sarrazin; Johannes Vermehren; Oliver Waidmann
Journal:  Liver Cancer       Date:  2018-03-01       Impact factor: 11.740

6.  High Expression of SLC41A3 Correlates with Poor Prognosis in Hepatocellular Carcinoma.

Authors:  Qian Li; Dan-Lei Xiong; Heng Wang; Wei-Li Jin; Ying-Yu Ma; Xiao-Ming Fan
Journal:  Onco Targets Ther       Date:  2021-05-05       Impact factor: 4.147

7.  Case report: 8 years after liver transplantation: de novo hepatocellular carcinoma 8 months after HCV clearance through IFN-free antiviral therapy.

Authors:  Giuliano Ramadori; Patrizia Bosio; Federico Moriconi; Ihtzaz A Malik
Journal:  BMC Cancer       Date:  2018-03-06       Impact factor: 4.430

8.  Long-term follow-up of clinical trial patients treated for chronic HCV infection with daclatasvir-based regimens.

Authors:  K Rajender Reddy; Stanislas Pol; Paul J Thuluvath; Hiromitsu Kumada; Joji Toyota; Kazuaki Chayama; James Levin; Eric J Lawitz; Adrian Gadano; Wayne Ghesquiere; Guido Gerken; Maurizia R Brunetto; Cheng-Yuan Peng; Marcelo Silva; Simone I Strasser; Jeong Heo; Fiona McPhee; Zhaohui Liu; Rong Yang; Misti Linaberry; Stephanie Noviello
Journal:  Liver Int       Date:  2017-10-12       Impact factor: 5.828

9.  Impact of COVID-19 pandemic on surveillance of hepatocellular carcinoma: A study in patients with chronic hepatitis C after sustained virologic response.

Authors:  Hidenori Toyoda; Satoshi Yasuda; Seiki Kiriyama; Makoto Tanikawa; Yasuhiro Hisanaga; Akira Kanamori; Shusuke Kitabatake; Satoshi Yamamoto; Shohei Shiota; Manabu Furoi; Takahiro Koyabu; Daiju Furukawa; Takashi Kumada; Yoshio Sumida
Journal:  GastroHep       Date:  2020-09-03

10.  Characteristics and Prognosis of De Novo Hepatocellular Carcinoma After Sustained Virologic Response.

Authors:  Hidenori Toyoda; Atsushi Hiraoka; Haruki Uojima; Akito Nozaki; Noritomo Shimada; Koichi Takaguchi; Hiroshi Abe; Masanori Atsukawa; Kentaro Matsuura; Toru Ishikawa; Shigeru Mikami; Tsunamasa Watanabe; Ei Itobayashi; Kunihiko Tsuji; Taeang Arai; Satoshi Yasuda; Makoto Chuma; Tomonori Senoh; Akemi Tsutsui; Tomomi Okubo; Takuya Ehira; Takashi Kumada; Junko Tanaka
Journal:  Hepatol Commun       Date:  2021-05-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.